Short answer: The era of cheap, widely available compounded semaglutide is largely over. Once the FDA declared the semaglutide shortage resolved in February 2025, the legal basis that let pharmacies mass-produce copies of Ozempic and Wegovy disappeared, and through 2025 and 2026 the agency steadily tightened enforcement against telehealth companies still selling it. Compounding hasn’t vanished entirely — a narrow path remains when a specific patient genuinely can’t use the approved drug — but “compounded semaglutide because it’s cheaper” is no longer a legitimate, low-risk option the way it briefly was. If you’re taking it or considering it, the most useful thing you can do is understand what you’re actually being sold and ask a few pointed questions.
First, what “compounded” even means here
A compounded drug is one a licensed pharmacy mixes to order, rather than a finished product manufactured and approved by the FDA. There are two main categories. 503A pharmacies compound for an individual patient against a specific prescription. 503B outsourcing facilities make larger batches under tighter manufacturing standards. Neither produces an FDA-approved product: compounded drugs do not go through the FDA’s premarket review for safety, effectiveness, and quality before they reach patients (FDA).
For most of 2022 through 2024, that distinction got blurry. Demand for semaglutide — the active ingredient in Ozempic and Wegovy — far outstripped supply, and the FDA placed it on its official drug shortage list. Federal law carves out an exception during a shortage: compounders are generally allowed to make versions of a drug that would otherwise be off-limits as a “copy” of an approved product. That exception is what powered the explosion of compounded semaglutide sold through telehealth platforms, often at a fraction of the brand-name price. It was legal precisely because there was a shortage.
What changed
The shortage ended, and with it the legal foundation.
On February 21, 2025, the FDA declared the semaglutide shortage resolved and removed the drug from its shortage list, having determined that supply could meet current and projected demand (McDermott Will & Emery). To avoid abruptly cutting off patients mid-treatment, the agency set short wind-down windows rather than stopping compounding overnight: 503A pharmacies had until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, to stop compounding semaglutide injection products (FDA). After those dates, the shortage exception no longer applied, and producing what are essentially copies of the approved drug fell outside the rules.
That is the single most important change. The compounded semaglutide that filled the gap during the shortage was not a permanent alternative product — it was a temporary, shortage-dependent workaround, and the condition that made it lawful has been removed.
The enforcement escalation through 2025 and 2026
Plenty of telehealth companies kept selling compounded GLP-1 products after the deadlines passed, and the FDA’s response grew progressively firmer.
In September 2025, the agency issued more than 55 warning letters to online sellers of compounded GLP-1 medications, largely over misleading direct-to-consumer advertising (Pharmacy Times). In early 2026 the FDA went further: it announced plans to restrict the active pharmaceutical ingredients used in compounded GLP-1 drugs being “mass-marketed” as alternatives to approved medicines, and it intensified its crackdown on false or misleading claims, warning that companies failing to fix violations could face seizure or injunction “without further notice” (AJMC). The drugmaker Novo Nordisk has also pursued litigation against telehealth companies it accuses of continuing to mass-compound semaglutide (Pharmacy Times).
The practical takeaway for a reader isn’t to track every legal filing. It’s that the regulatory direction has been consistent and one-way: tighter, not looser. A company still marketing compounded semaglutide as a cheaper, “just-as-good” version of Wegovy in 2026 is operating against the current, not with it.
The narrow path that still exists
Compounding did not become illegal — only the shortage-driven, mass-market version did. A 503A pharmacy can still compound semaglutide for an individual patient when a prescriber documents that the compounded version makes a meaningful clinical difference the approved drug can’t provide (McDermott Will & Emery). The classic examples are things like removing an inactive ingredient a patient is allergic to, though the FDA has noted those specific modifications may not commonly apply to GLP-1 drugs.
This is a genuinely narrow lane, and it’s worth being honest about why. “Personalized dosing” has become a popular marketing phrase, but wanting a dose between the manufacturer’s standard steps, or simply wanting a lower price, is generally not the kind of documented clinical necessity the exception was built for. If a service is offering compounded semaglutide to essentially anyone who fills out a form, that is a signal to slow down and ask what legal basis they’re relying on.
Why the FDA is concerned about the compounded versions
Cost and convenience are real, and it’s worth understanding the trade-off honestly rather than dismissively. The FDA’s concerns are specific and documented.
No premarket review. Because compounded drugs aren’t FDA-approved, no one has independently verified their safety, quality, or potency before they’re sold (FDA). With a brand-name pen, the dose in the device is the dose on the label. With a compounded vial, you are trusting the individual pharmacy’s process.
Salt forms that aren’t the approved drug. The FDA has reported that some compounded products use salt forms of semaglutide — semaglutide sodium and semaglutide acetate — which are chemically different active ingredients from the semaglutide base in the approved medicines. The agency has said it lacks information on whether these salts behave the same way in the body and is “not aware of any lawful basis” for using them in compounding (FDA). In other words, a product labeled “semaglutide” may not contain the same molecule that was studied in the trials.
Dosing errors. This is the most concrete safety problem. In a 2024 alert, the FDA warned of dosing errors with compounded injectable semaglutide, including patients who drew up many times their intended dose. Some errors came from people unfamiliar with measuring an injection; others from providers and patients mis-converting between milligrams, milliliters, and “units.” Reported adverse events ranged from nausea, vomiting, and abdominal pain to dehydration, fainting, acute pancreatitis, and gallstones, and some cases required hospitalization (FDA). A prefilled, fixed-dose pen largely designs this category of error out; a multi-dose vial and a syringe puts it back in.
None of this means every compounded product harmed someone — most people who used them did not have a serious event. But the risk profile is genuinely different from an approved, prefilled product, and that difference is the whole point.
What to ask
If you’re currently on compounded semaglutide, or a service is offering it to you, these are the questions worth asking your clinician or the pharmacy directly. None of them require medical expertise to ask.
- Is this an FDA-approved medication or a compounded one? This is the first and most clarifying question. If the answer is compounded, everything below follows.
- If it’s compounded, what’s the documented clinical reason I can’t use the approved drug? A legitimate answer points to a specific patient need. “It’s cheaper” or “it’s more convenient” is not a clinical reason, and post-shortage, it’s not a lawful basis for compounding.
- Which type of pharmacy is making it, and where is it licensed? 503A or 503B, and in which state. You’re entitled to know who is actually compounding your medication.
- What exactly is the active ingredient? You want semaglutide base — the same active ingredient as the approved drugs — not semaglutide sodium or semaglutide acetate.
- Where is the active ingredient sourced and is it tested? Reputable pharmacies can tell you about their supplier and their potency and sterility testing.
- How is my dose measured and delivered? A prefilled syringe or pen is far harder to mis-dose than drawing from a vial. If it’s a vial, ask exactly how the dose converts from milligrams to what you draw up — and have someone walk you through it.
- What happens if this product is discontinued? Given the regulatory trajectory, ask what the plan is if your source stops compounding, so you’re not left scrambling.
- Now that approved supply has recovered, what are my approved options and what would they cost? With Ozempic and Wegovy more available, and with manufacturer savings programs and direct-pay options that have emerged, the price gap may be smaller than it was during the shortage. It’s worth a real comparison.
The bottom line
The story of compounded semaglutide is, at its core, a story about a shortage that ended. While supply was tight, compounding filled a real gap, and for many people it was the only way to access the medication at all. That window has closed: the FDA resolved the shortage in early 2025, set deadlines for compounders to stop, and has spent the time since enforcing the new reality against companies that kept selling. A limited, individualized form of compounding survives for patients with a genuine, documented clinical need, but the mass-market product does not.
If your weight or diabetes management currently runs through compounded semaglutide, this isn’t cause for alarm — it’s a reason for a conversation. Approved options are more available than they were, the questions above will tell you a great deal about what you’re actually taking, and your clinician can help you weigh the trade-offs for your specific situation. The regulatory landscape is still shifting, with further restrictions proposed, so the safest stance is an informed one: know what’s in the vial, know why you’re using it, and know what your approved alternatives are.
References
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
- U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize.
- U.S. Food and Drug Administration. FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products (2024).
- McDermott Will & Emery. Semaglutide Shortage Resolved.
- Pharmacy Times. FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Take-Down. What’s Next?
- The American Journal of Managed Care (AJMC). FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads.